Intarcia licenses ITCA 650 to Servier ex-U.S., Japan

Intarcia Therapeutics Inc. (Boston, Mass.) has granted Servier (Neuilly-sur-Seine, France) exclusive development and commercialization rights to implantable diabetes therapy ITCA 650 outside the U.S. and Japan.

Intarcia will receive $171 million up front and is eligible for $230 million in near-term regulatory milestones. The deal also includes longer-term milestones totaling $650 million and tiered royalties ranging from low double digits up to the mid-30s. ...